SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions

Represents potential penetration into ~ 20% of the U.S. institutional market, while broadening access across long-term care and outpatient facilities

U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli^™ as the first FDA-approved ready-to-use oral suspension

Read more at globenewswire.com